In mice, HFD reduces Enho mRNA levels concomitantly with the development of hepatic steatosis, while adropin overexpression attenuates HFD-derived hepatic steatosis, reduces weight gain, increases whole-body fatty acid oxidation, and improves insulin sensitivity [48]. Here, ENHO is linked to fatty liver disease.